GENERATION HD2

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease.

Approved information available in German only: follow this LINK

Status: recruiting completed.

See also the information on clinicaltrials.gov